Medtronic launches GI Genius AI colonoscope

Medtronic (NYSE:MDT) said yesterday that it launched the GI Genius endoscopy module for detecting colorectal polyps in the treatment of colorectal cancer.

The GI Genius is designed to use artificial intelligence to highlight pre-cancerous lesions with a visual marker, something Medtronic said can increase colorectal polyp detection rates. The Fridley, Minn.-based company said it is the first system of its kind worldwide for detecting colorectal polyps.
Medtronic said that in order to launch the GI Genius, it entered into a worldwide distribution agreement with Cosmo Pharmaceuticals. Cosmo manufactures the GI Genius and its AI software.
The GI Genius system has CE Mark approval and is available in select European markets. However, it has not yet won FDA clearance for commercialization in the U.S.
“Medtronic is focused on preventing colorectal cancer by early detection of pre-cancerous polyps with AI-assisted technologies,” VP & GM of Medtronic’s gastrointestinal & hepatology business Giovanni Di Napoli said in prepared remarks. “The GI Genius module automatically detects polyps, including small flat polyps that may go undetected thus increasing accuracy and reducing the risk of interval cancers which can occur between colonoscopies.”